Cannabinoid Research Firm Cannabis Science, Inc. Could Go Under
By Anne Holland [Updated as of 4/25/12] According to its annual 2012 report filed today, Cannabis Science, Inc. (PINK:CBIS), may be in danger of shutting its doors. The company’s Form 10-K stated, “At this time, our ability to generate any significant revenues continues to be uncertain. There is substantial doubt about our ability to continue as a going concern.” Although this type of doom-saying is normal for financial filings, which must include worst-case scenarios, Cannabis Science’s financials, as presented, do not appear to be encouraging. The company’s stock has been hovering just over 5 cents all day, compared to nearly 11 cents a year ago.
Despite this uncertainty, the company, which develops cannabinoid-based (CBD) therapies for the treatment of cancer and infectious diseases, is continuing to fight on. Just last month, it announced the appointment of another member of its scientific advisory board, Michael McGrath, a professor of medicine and lab medicine at the University of California, San Francisco. As we’ve reported in the past, credible medical studies have shown that CBDs may be effective in fighting some forms of cancer. The overall future of CBD-based treatments may be very bright indeed … but the legal situation surrounding them is still murky.
Although Cannabis Science only has two full-time employees, its general and administrative expenses increased by more than $1.2 million during 2012, from $3 million to $4.3 million, largely due to management and consulting fees owed under purchase agreements related to its acquisitions of GGECO University Inc and Cannabis Consulting, Inc. in the first quarter of 2012.
Several investor advisory publications and bloggers are using Cannabis Science as an example, saying MMJ-related stocks are altogether too risky for investors.
However, we feel this is too simplistic.
While the stock market itself is inherently risky, and due to legal factors MMJ-related stocks are even more so, some medical cannabis companies may be worth looking into. The key is to find companies with growing revenues in ancillary industries that do not depend entirely on FDA or other federal approval to continue.
A dispensary in Nevada that has been hoping to open since February is considering filing [click to continue...]
Nineteen Washington State marijuana stores face suspensions and fines after they failed to properly check [click to continue...]
Concerned with what might happen if voters legalize recreational marijuana at the ballot next year, [click to continue...]
After evaluating a fatal accident that took place last year in Denver, the Center for [click to continue...]
Israel, one of the world’s leading countries on medical cannabis research, will soon be dispensing [click to continue...]
Minnesota’s third medical cannabis dispensary has opened despite the low number of patients registered to [click to continue...]
A business run by the president of the California Cannabis Industry Association was raided and [click to continue...]
As Illinois’ medical marijuana industry ramps up, regulatory officials are preparing to start following medical [click to continue...]
A week after Colorado shot down an attempt to add post-traumatic stress disorder as a [click to continue...]
Rhode Island’s three medical cannabis dispensaries must be pleased: In the past two and a [click to continue...]
Justin Trudeau, a candidate for prime minister of Canada, came to the defense of dispensaries [click to continue...]
Hurry up and wait. That appears to be the situation for medical marijuana businesses in [click to continue...]
A working group overseen by California’s lieutenant governor has issued a report outlining 58 policy [click to continue...]
United for Care, which was behind the failed 2014 campaign to legalize medical cannabis in [click to continue...]